Phase 3 Clinical Trials With Primary Completion Dates in July 2023
This is a list of Phase 3 trials with primary completion dates in July 2023 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | 2023-07-01 | Phase 3 | NCT04776746 | Open-Label Extension Study of Trofinetide for Rett Syndrome |
| ALLK | Allakos Inc. | 2023-07-01 | Phase 3 | NCT04620811 | An Extension Study of Lirentelimab in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis) |
| ARAV | Aravive, Inc. | 2023-07-01 | Phase 3 | NCT04729608 | Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer |
| BLCO | Bausch + Lomb Corporation | 2023-07-01 | Phase 3 | NCT05360784 | "Efficacy and Safety of Brimonidine Tartrate Preservative-Free Formulation in Adults With Ocular Redness" |
| CRNX | Crinetics Pharmaceuticals, Inc. | 2023-07-01 | Phase 3 | NCT04837040 | A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly |
| IBRX | ImmunityBio, Inc. | 2023-07-01 | Phase 3 | NCT03520686 | QUILT 2.023: A Study of N-803 in Combination With Current Standard of Care vs Standard of Care as First-Line Treatment for Patients With Stage 3 or 4 NSCLC. |
| IONS | Ionis Pharmaceuticals, Inc. | 2023-07-01 | Phase 3 | NCT04568434 | A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) Administered to Patients With Familial Chylomicronemia Syndrome (FCS) |
| KRTX | Karuna Therapeutics, Inc. | 2023-07-01 | Phase 3 | NCT04820309 | An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5) |
| RLMD | Relmada Therapeutics, Inc. | 2023-07-01 | Phase 3 | NCT04855760 | Safety of REL-1017 for Major Depressive Disorder |
| SUPN | Supernus Pharmaceuticals, Inc. | 2023-07-01 | Phase 3 | NCT04143217 | Open-label Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD |
| TBPMF | Tetra Bio-Pharma Inc. | 2023-07-01 | Phase 3 | NCT04001010 | Safety and Efficacy of Inhaled Synthetic THC/CBD for Improving Physical Functioning and for Modulating Cachexia Progression in Patients With Advanced Cancer and Associated Cachexia |